| Literature DB >> 32767657 |
Xiang Ren1, Yu Li1, Xiaokun Yang1, Zhili Li1, Jinzhao Cui1, Aiqin Zhu1, Hongting Zhao1, Jianxing Yu1, Taoran Nie1, Minrui Ren1, Shuaibing Dong1, Ying Cheng1, Qiulan Chen1, Zhaorui Chang1, Junling Sun1, Liping Wang1, Luzhao Feng1, George F Gao1, Zijian Feng1, Zhongjie Li1.
Abstract
BACKGROUND: Between mid-January and early February, provinces of mainland China outside the epicentre in Hubei province were on high alert for importations and transmission of COVID-19. Many properties of COVID-19 infection and transmission were still not yet established.Entities:
Keywords: COVID-19; China; epidemiology; pre-symptomatic Transmission
Year: 2020 PMID: 32767657 PMCID: PMC7436222 DOI: 10.1111/irv.12787
Source DB: PubMed Journal: Influenza Other Respir Viruses ISSN: 1750-2640 Impact factor: 4.380
Figure 1Panel A: occurrence by date of illness onset of cases identified outside of Hubei province in persons with a history of travel from Wuhan in the 14 d prior to onset. Panel B: occurrence by date of illness onset of cases identified outside of Hubei province in persons without a history of travel from Wuhan in the 14 d prior to onset. Panel C: augmented occurrence (yellow bars) by date of illness onset of cases identified outside of Hubei province in persons with a history of travel from Wuhan in the 14 d prior to onset with back filled cases considering delays between illness onset and seeking care and being tested
Figure 2Panel A: incubation period distribution based on 98 cases identified outside Hubei province and reporting recent travel from Wuhan. The grey line indicates the empirical fitted lognormal distribution, and the solid black line indicates the fitted lognormal distribution after correction for epidemic growth. Panel B: serial interval distribution based on 80 observed transmission events. The grey bars show the raw data, the grey line indicates the empirical fitted gamma distribution, and the solid black line indicates the fitted gamma distribution after correction for epidemic growth
Figure 3Transmission events used to infer the occurrence of pre‐symptomatic transmission. Dots indicate the dates of onset of primary and secondary cases, and the shaded area in each row indicates the period of exposure of the secondary case to the primary case during which the secondary infection is thought to have occurred. Brackets indicate the exposure window when the primary case was thought to have been infected. Data were resolved to the nearest day, and so transmission windows are plotted from the start of the first date to the end of the last date, onset dates are plotted in the middle of the corresponding day, and if the secondary onset date is the same as the primary onset date, then the former is offset slightly so that both can be seen
Characteristics of novel coronavirus infected patients identified in other provinces in China outside of Hubei through the Chinese Public Health Event Surveillance System as of 30 January 2020
| Characteristics | Cluster primary cases and sporadic cases (n = 201) | Cluster secondary cases (n = 80) | ||
|---|---|---|---|---|
| Number | % | Number | % | |
| Age, years | ||||
| <15 | 0/197 | 0 | 1/79 | 1 |
| 15‐44 | 96/197 | 49 | 37/79 | 47 |
| 45‐64 | 80/197 | 41 | 32/79 | 41 |
| ≥65 | 21/197 | 11 | 9/79 | 11 |
| Male | 120/200 | 60 | 34/80 | 43 |
| Underlying conditions | 29/95 | 31 | 6/18 | 33 |
| Hypertension | 12/95 | 13 | 4/18 | 22 |
| Diabetes | 6/95 | 6 | 1/18 | 6 |
| Severity at day of analysis | ||||
| Mild | 110/166 | 66 | 65/75 | 87 |
| Severe | 43/166 | 26 | 9/75 | 12 |
| Critical | 12/166 | 7 | 1/75 | 1 |
| Death | 1/166 | 0.6 | 0/75 | 0 |
| Symptoms at illness onset | ||||
| Fever | 168/183 | 92 | 57/64 | 89 |
| Headache | 26/29 | 90 | 6/10 | 60 |
| Fatigue | 70/96 | 73 | 20/31 | 65 |
| Dry cough | 75/109 | 69 | 25/38 | 66 |
| Myalgia | 43/73 | 59 | 14/26 | 54 |
| Nausea | 4/7 | 57 | 0/3 | 0 |
| Chill | 38/77 | 49 | 7/19 | 37 |
| Sore throat | 33/71 | 46 | 8/22 | 36 |
| Chest distress | 16/60 | 27 | 3/16 | 19 |
| Dizziness | 11/50 | 22 | 0/13 | 0 |
| Tachypnoea | 12/54 | 22 | 2/13 | 15 |
| Loss of appetite | 9/46 | 20 | 1/14 | 7 |
| Dyspnoea | 5/47 | 11 | 0/13 | 0 |
| Diarrhoea | 6/53 | 11 | 2/15 | 13 |
| Vomiting | 3/52 | 6 | 2/15 | 13 |
| Pneumonia (radiology) | 146/152 | 96 | 35/47 | 74 |
| White blood cell count | ||||
| Decreased (<4 × 109/L) | 35/141 | 25 | 10/46 | 22 |
| Normal (4‐10 × 109/L) | 102/141 | 72 | 35/46 | 76 |
| Increased (>10 × 109/L) | 4/141 | 3 | 1/46 | 2 |
| Lymphocyte count | ||||
| Decreased | 64/125 | 51 | 23/40 | 58 |
| Normal | 48/125 | 38 | 15/40 | 38 |
| Increased | 13/125 | 10 | 2/40 | 5 |
For patients having clinical test results of both lymphocyte count and proportion, a normal lymphocyte count refers to both the lymphocyte count within the range of 1‐4 × 109/L and the lymphocyte proportion to be 20%‐40%. Patients with either lymphoycyte count or lymphocyte proportion lower or higher than the normal range will be classified as “decreased” or “increased,” respectively.
Category of lymphocyte count is determined by both the count and proportion of lymphocyte (the proportion is derived as lymphocyte count divided by white blood cell count) in the blood test.